Abstract
Its limited therapeutic effect on hypoxic and refractory solid tumors has hindered the practical application of photodynamic therapy (PDT). Herein, we report our investigation of an osmium-peroxo complex (Os2), which is inactive in the dark, but upon light irradiation, can release a peroxo ligand O2•−, and is transformed into a cytotoxic osmium complex (Os1). The osmium-peroxo complex Os2 produces O2•− under light irradiation even in the absence of oxygen, and retains its phototoxicity in hypoxic tumors. Os1 is cytotoxic in the presence or absence of irradiation, behaves as a chemotherapeutic drug. The light-activated Os2 induces distinct ferroptosis, which is mediated by GSH degradation, lipid peroxide accumulation and down-regulation of glutathione peroxidase 4 (GPX4). In addition, Os2 causes photocatalytic oxidation of endogenous 1,4-dihydronicotinamide adenine dinucleotide (NADH) in living cancer cells, leading to ferroptosis. In vivo studies have confirmed that the Os2 can effectively inhibit the growth of solid hypoxic tumors in mice. A new strategy is proposed for the treatment of hypoxic tumors with metal-based drugs.